Brought to you by 
Abivax goes public netting €54.5mm
18 Sep 2017
Executive Summary
French antivirals developer Abivax netted €54.5mm ($61.9mm) through its initial public offering of 2.7mm shares (including the overallotment) at €21.30, the middle of its €18.26-24.34 range, on the Paris Euronext exchange.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Large Molecule
-
Drug Discovery Tools
- Genomics-Proteomics
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Abivax goes public netting €54.5mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice